Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

Rhea-AI Summary

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotech firm, announced its participation in two significant investor conferences. The Cowen 43rd Annual Health Care Conference will occur on March 6, 2023, at 8:10 AM PT, while the Oppenheimer 33rd Annual Healthcare Conference is set for March 14, 2023, at 9:00 AM PT. Webcasts will be available on their website, along with replays accessible for 30 days. Allogene is known for developing off-the-shelf CAR T cell therapies for cancer. For more details, visit www.allogene.com.

SOUTH SAN FRANCISCO, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences.

Cowen 43^rd Annual Health Care Conference
Monday, March 6, 2023
8:10AM PT/11:10AM ET

Oppenheimer 33^rd Annual Healthcare Conference
Tuesday, March 14, 2023
9:00AM PT/12:00PM ET

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for cancer and the potential benefits of AlloCAR T. Various factors may cause material differences between Allogene’s expectations and actual results, including, risks and uncertainties related to: our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading of its Form 10-K for the year ended December 31, 2022.Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com

Jessica Bernstein
Senior Manager, Corporate and Internal Communications
Jessica.Bernstein@allogene.com

FAQ

What are the dates for the upcoming investor conferences for Allogene (ALLO)?

Allogene will participate in the Cowen 43rd Annual Health Care Conference on March 6, 2023, and the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023.

What time will Allogene present at the Cowen Conference?

Allogene will present at the Cowen 43rd Annual Health Care Conference at 8:10 AM PT on March 6, 2023.

When will the Oppenheimer Conference presentation take place for Allogene (ALLO)?

Allogene's presentation at the Oppenheimer 33rd Annual Healthcare Conference is scheduled for March 14, 2023, at 9:00 AM PT.

Where can I watch Allogene's investor conference webcasts?

Webcasts for Allogene's investor conferences will be available on their website under the Investors tab in the News and Events section.

How long will the conference replays be available for Allogene (ALLO)?

Replays of Allogene's conference presentations will be available on their website for approximately 30 days after the live event.